Geode Capital Management LLC Decreases Stock Holdings in Daré Bioscience, Inc. (NASDAQ:DARE)

Geode Capital Management LLC lowered its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 91.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 89,060 shares of the biotechnology company’s stock after selling 917,501 shares during the period. Geode Capital Management LLC owned about 1.04% of Daré Bioscience worth $289,000 as of its most recent SEC filing.

Separately, Renaissance Technologies LLC boosted its holdings in shares of Daré Bioscience by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 778,700 shares of the biotechnology company’s stock worth $262,000 after buying an additional 15,800 shares during the last quarter. 6.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Price Performance

NASDAQ:DARE opened at $3.33 on Tuesday. The company has a market capitalization of $28.97 million, a P/E ratio of -5.64 and a beta of 1.28. The business has a fifty day simple moving average of $3.36 and a two-hundred day simple moving average of $3.43. Daré Bioscience, Inc. has a 1 year low of $2.67 and a 1 year high of $7.56.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.